Royalty Pharma plc Non Peo Neo Avg Total Comp Amt
Royalty Pharma plc (RPRX) reported Non Peo Neo Avg Total Comp Amt of $1.32 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-10.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-10
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $1.32M DEF 14A · filed 2026-04-10 |
| 2024-12-31 | $1.26M DEF 14A · filed 2026-04-10 |
| 2023-12-31 | $4.56M DEF 14A · filed 2026-04-10 |
| 2022-12-31 | $4.35M DEF 14A · filed 2026-04-10 |
| 2021-12-31 | $3.84M DEF 14A · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |